Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer

DARMSTADT, Germany, July 1, 2016 /PRNewswire/ --





Not intended for UK- or US-based media

WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST 


- Phase III study shows response rate of 61.1% for patients treated with Erbitux
plus FOLFOX 
- 31% decrease in risk of disease progression and 24% decrease in risk of death was
achieved with addition of Erbitux to FOLFOX  
- First prospective study to evaluate Erbitux in RAS wild-type patients 



Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). The results demonstrate that Erbitux(R) (cetuximab) plus FOLFOX statistically significantly improves outcomes, including progression-free survival (PFS; primary endpoint), overall survival (OS) and best overall response rate (bORR), compared with FOLFOX alone.[1]

Notably, compared with those receiving FOLFOX alone, patients in the study receiving Erbitux plus FOLFOX experienced:[1]


- a bORR of 61.1% (versus 39.5%; odds ratio [OR]: 2.41; p

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234